Intestinal Failure Unit, Salford Royal NHS Foundation Trust, Salford, United Kingdom; Gastroenterology Department, Salford Royal NHS Foundation Trust, Salford, United Kingdom; Manchester Academic Health Sciences Centre, University of Manchester, Manchester, United Kingdom.
Intestinal Failure Unit, Salford Royal NHS Foundation Trust, Salford, United Kingdom.
Clin Nutr. 2018 Dec;37(6 Pt A):1967-1975. doi: 10.1016/j.clnu.2018.09.008. Epub 2018 Sep 22.
BACKGROUND & AIMS: Severe gastrointestinal dysmotility (GID) is a significant cause of chronic intestinal failure (CIF) with unclear benefits of sub-classifying into Chronic Intestinal Pseudo-obstruction (CIPO) and non-CIPO sub-types. We compared outcomes between CIPO and non-CIPO sub-types in a tertiary cohort of patients with CIF resulting from severe GID.
Adults with primary GID, commenced on home parenteral nutrition (HPN) over a 16-year period at a national referral centre, were included. All patients satisfied GID clinical criteria which mandated evidence of small bowel involvement either objectively (abnormal antroduodenal manometry) or pragmatically (failure to progress on small bowel feeding). Clinical outcomes including HPN dependency and survival were compared between CIPO and non-CIPO sub-types.
Patients with primary GID requiring HPN (n = 45, age 38 ± 2, 33 females, 23/45 (51%) CIPO, 22/45 (49%) non-CIPO) were included. Patients with CIPO had more surgical interventions (P = 0.03), higher incidence of bacterial overgrowth (P = 0.006), greater parenteral energy (P = 0.02) and volume requirements (P = 0.05). Overall, during a mean 6 years' follow-up, 36/45 (80%) patients remained HPN dependent. Multivariate analyses confirmed that the non-CIPO sub-type (P = 0.04) and catheter related blood stream infections/1000 days (P = 0.01) were predictive factors for time to discontinuing HPN. Overall 5-year survival on HPN was 85%, with no difference between sub-types (P = 0.83).
The CIPO sub-type is associated with higher HPN dependency and should be recognized as a separate entity in severe GID. In multidisciplinary settings with continuous close monitoring of risks and benefits, our data confirm HPN is a safe, life-preserving therapy in severe GID related CIF.
严重的胃肠道动力障碍(GID)是慢性肠衰竭(CIF)的一个重要原因,其分为慢性假性肠梗阻(CIPO)和非 CIPO 亚型,目前尚不清楚这两种亚型的分类对治疗有何益处。我们比较了在一个因严重 GID 导致 CIF 的三级队列中 CIPO 和非 CIPO 亚组患者的结局。
纳入在国家转诊中心接受肠外营养(HPN)治疗的原发性 GID 成人患者,研究时间为 16 年。所有患者均满足 GID 临床标准,即需要有小肠受累的证据,包括客观证据(十二指肠胃测压异常)或实用证据(小肠喂养无法进展)。比较 CIPO 和非 CIPO 亚组之间的 HPN 依赖和生存等临床结局。
纳入 45 例原发性 GID 需要 HPN 的患者(年龄 38±2 岁,女性 33 例,23/45 例(51%)为 CIPO,22/45 例(49%)为非 CIPO)。CIPO 患者的手术干预更多(P=0.03),细菌过度生长的发生率更高(P=0.006),需要更多的肠外能量(P=0.02)和容量(P=0.05)。总体而言,在平均 6 年的随访期间,36/45 例(80%)患者仍依赖 HPN。多变量分析证实,非 CIPO 亚型(P=0.04)和导管相关血流感染/1000 天(P=0.01)是停止 HPN 的时间的预测因素。HPN 总体 5 年生存率为 85%,两种亚型之间无差异(P=0.83)。
CIPO 亚组与更高的 HPN 依赖性相关,应被视为严重 GID 中的一种独立实体。在多学科环境中,持续密切监测风险和获益,我们的数据证实 HPN 是严重 GID 相关 CIF 的一种安全、挽救生命的治疗方法。